- Home
- Companies
- Zymeworks Inc
- Products
- Zymelink - Enhance Therapeutic Response ...
Zymelink - Enhance Therapeutic Response Cell
with a modular suite of proprietary cytotoxins (cell-killing compounds), stable linkers, and conjugation technologies. A broader window of opportunity. Deliver potent cell-killing compounds specifically to diseased target cells with optimal safety and efficacy. ZymeLink™, a next-generation antibody drug conjugate (ADC) platform, is a suite of proprietary cytotoxins (cell-killing compounds), stable linkers, and conjugation technologies. ZymeLink™ is compatible with traditional antibodies, proteins, and the Azymetric™ bispecific antibody platform, creating multifunctional therapeutics designed to overcome the limitations of existing ADCs.
Develop next-generation antibody drug conjugates with broad therapeutic windows.
ZymeLink™ antibody drug conjugates are designed to:
- Closely resemble natural antibodies with improved pharmacokinetics, stability, and cytotoxin exposure over alternative ADC technologies
- Exhibit increased tolerability
- Demonstrate a broad therapeutic window, a key competitive advantage over existing ADC platforms
The ZymeLink ADC platform is designed to combine the specificity of traditional and bispecific antibodies with the strength of potent cytotoxins (cell-killing compounds) to treat cancer and other diseases.
Zymeworks is developing diverse classes of proprietary cytotoxins with potent anti-tumor activity against a broad range of cancer cell types. Innovative, stable linkers chemically attach cytotoxins to a variety of targeted therapeutics, including traditional antibodies, proteins, and the Azymetric™ bispecific antibody platform. Each linker is tailored to a specific cytotoxin to enable optimal safety and efficacy of the ADC.
Together, the ZymeLink™ ADC platform and Azymetric™ bispecific antibody platform are designed for the development of best-in-class, life-changing medicines for patients